Literature DB >> 10606360

Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis.

A Karim1, D S Tolbert, T L Hunt, R C Hubbard, K M Harper, G S Geis.   

Abstract

OBJECTIVE: To determine the effects of celecoxib, a specific inhibitor of cyclooxygenase 2 (COX-2) on the renal clearance and plasma pharmacokinetic profile of stable methotrexate (MTX) doses in patients with rheumatoid arthritis (RA).
METHODS: Fourteen adult female patients with RA taking a stable weekly dose of MTX (5 to 15 mg/wk) for a minimum of 3 months were randomized to receive concomitantly either celecoxib (200 mg BID) or placebo for a period of 7 days in a single blind, 2 period crossover study of MTX pharmacokinetics and renal clearance.
RESULTS: The plasma pharmacokinetic profile of MTX did not change significantly when celecoxib or a placebo was coadministered. The mean renal clearance of MTX alone, 7.98+/-2.18 l/h, was virtually unchanged by coadministration of celecoxib (7.94+/-1.61 l/h) or placebo (7.97+/-1.19 l/h).
CONCLUSION: Celecoxib has no significant effect on the pharmacokinetics or renal clearance of MTX in patients with RA, although these results should be confirmed in prospective studies of elderly and renally impaired patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10606360

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

Review 1.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

Review 2.  Drug dosage in the elderly: dermatological drugs.

Authors:  Anna Flammiger; Howard Maibach
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.

Authors:  Christopher C Coss; Amanda Jones; James T Dalton
Journal:  Invest New Drugs       Date:  2016-04-22       Impact factor: 3.850

Review 4.  Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.

Authors:  N M Davies; A J McLachlan; R O Day; K M Williams
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 5.  Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.

Authors:  D Clemett; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 6.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 7.  Clinical use and pharmacological properties of selective COX-2 inhibitors.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

8.  The concomitant use of meloxicam and methotrexate does not clearly increase the risk of silent kidney and liver damages in patients with rheumatoid arthritis.

Authors:  Hee-Jin Park; Min-Chan Park; Yong-Beom Park; Soo-Kon Lee; Sang-Won Lee
Journal:  Rheumatol Int       Date:  2013-12-22       Impact factor: 2.631

9.  Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function.

Authors:  Jin Su Park; Min-Chan Park; Yong-Beom Park; Soo-Kon Lee; Sang-Won Lee
Journal:  Clin Rheumatol       Date:  2014-06-20       Impact factor: 2.980

Review 10.  Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?

Authors:  Charles J Rosser; Micah Gaar; Stacy Porvasnik
Journal:  BMC Cancer       Date:  2009-07-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.